Heron Therapeutics (HRTX) Expected to Announce Quarterly Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is expected to issue its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $39.0310 million for the quarter. Heron Therapeutics has set its FY 2025 guidance at EPS.Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Friday, August 8th. The biotechnology company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $37.20 million for the quarter, compared to analysts’ expectations of $38.08 million. On average, analysts expect Heron Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Heron Therapeutics Stock Up 1.8%

NASDAQ HRTX opened at $1.16 on Monday. Heron Therapeutics has a 52 week low of $1.04 and a 52 week high of $2.68. The firm has a market capitalization of $212.64 million, a P/E ratio of -58.00 and a beta of 1.25. The company has a 50-day moving average price of $1.28 and a 200-day moving average price of $1.71.

Insider Buying and Selling

In other news, Director Adam Morgan bought 1,766,546 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average price of $1.50 per share, for a total transaction of $2,649,819.00. Following the purchase, the director owned 8,753,290 shares in the company, valued at approximately $13,129,935. The trade was a 25.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Rubric Capital Management Lp acquired 2,387,225 shares of the business’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $1.50 per share, with a total value of $3,580,837.50. Following the completion of the acquisition, the insider owned 29,100,728 shares in the company, valued at approximately $43,651,092. This represents a 8.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 5.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Heron Therapeutics

A number of institutional investors have recently added to or reduced their stakes in HRTX. Goldman Sachs Group Inc. grew its holdings in Heron Therapeutics by 57.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock valued at $2,263,000 after buying an additional 373,518 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Heron Therapeutics by 36.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 953,080 shares of the biotechnology company’s stock valued at $1,973,000 after buying an additional 256,637 shares in the last quarter. Rhumbline Advisers grew its holdings in Heron Therapeutics by 29.3% during the 2nd quarter. Rhumbline Advisers now owns 222,438 shares of the biotechnology company’s stock valued at $460,000 after buying an additional 50,344 shares in the last quarter. Prudential Financial Inc. grew its holdings in Heron Therapeutics by 231.0% during the 2nd quarter. Prudential Financial Inc. now owns 36,465 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 25,450 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Heron Therapeutics during the 2nd quarter valued at approximately $43,000. 80.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HRTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th. Needham & Company LLC reduced their price target on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wall Street Zen lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.